Crossmark

A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease

Crossref DOI link: https://doi.org/10.1038/s41380-018-0091-8

Published Online: 2018-07-09

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Hartl, Daniela

May, Patrick https://orcid.org/0000-0001-8698-3770
Gu, Wei

Mayhaus, Manuel

Pichler, Sabrina

Spaniol, Christian

Glaab, Enrico

Bobbili, Dheeraj Reddy

Antony, Paul

Koegelsberger, Sandra

Kurz, Alexander

Grimmer, Timo

Morgan, Kevin https://orcid.org/0000-0002-8217-2396
Vardarajan, Badri N.

Reitz, Christiane

Hardy, John

Bras, Jose

Guerreiro, Rita

Balling, Rudi

Schneider, Jochen G.

Riemenschneider, Matthias
License Information

Text and Data Mining valid from 2018-07-09
More Information

Article History

Received: 16 February 2018

Revised: 5 April 2018

Accepted: 11 April 2018

First Online: 9 July 2018

Compliance with ethical standards

:

: TG has reported in having received consulting fees from Actelion, Eli Lilly, MSD; Novartis, Quintiles, Roche Pharma, and lecture fees from Biogen, Lilly, Parexel, Roche Pharma, and also grants to his institution from Actelion and PreDemTech. The remaining authors declare that they have no conflict of interest.